A patient receiving dialysis. Picture: Mujahid Safodien 13 04 2012
THE Competition Commission has referred a complaint against Adcock Ingram Critical Care (AICC) to the Competition Tribunal over allegations of excessive pricing of products used in renal replacement therapy for kidney failure.
The alleged conduct relates to peritoneal dialysis and continuous renal replacement therapy (CRRT) products used in the treatment of kidney deterioration and kidney failure. The period under investigation runs from July 2019 to June 2024.
AICC is a division of Adcock Ingram and is involved in the manufacture and distribution of critical care products, including intravenous fluids and renal dialysis systems.
Renal dialysis performs key kidney functions when patients experience kidney failure. Peritoneal dialysis can be performed at home, while CRRT is mainly administered in intensive care units.
